Patents by Inventor Muralidhara Ramachandra

Muralidhara Ramachandra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS
    Publication number: 20240122904
    Abstract: The present invention relates to method of modulating TIGIT signaling pathway and PD-1 signaling pathway. The invention also encompasses the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the treatment of diseases or disorders mediated by both TIGIT signaling pathway and PD-1 signaling pathway.
    Type: Application
    Filed: November 22, 2023
    Publication date: April 18, 2024
    Inventors: Pottayil Govindan Nair SASIKUMAR, Muralidhara RAMACHANDRA, Seetharamaiah Setty Sudarshan NAREMADDEPALLI, Chennakrishnareddy GUNDALA
  • DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS
    Publication number: 20240100024
    Abstract: The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Application
    Filed: November 21, 2023
    Publication date: March 28, 2024
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Nagaraj Gowda
  • Method for treating diseases using SMARCA2/4 degraders
    Patent number: 11865114
    Abstract: The present invention provides a method of treating a disease or disorder with at least one SMARCA2/4 degrader, in a subject who are responders to such treatment based on the presence of tumor specific alterations described therein. The present invention also provides the methods for treating prostate cancer in the subjects who are likely to respond to treatment with SMARCA2/4 degraders.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: January 9, 2024
    Assignee: Aurigene Oncology Limited
    Inventors: Muralidhara Ramachandra, Leena Khare Satyam, Sanjita Sasmal, Susanta Samajdar
  • Method of Treating Cancer Using FABP5 Inhibitors
    Publication number: 20230414605
    Abstract: The present invention describes methods of treating cancer associated with a deregulated lymphocyte receptor signaling pathway by administering to a subject in need thereof a fatty acid-binding protein 5 (FABP5) inhibitor. The present invention relates to the method of treating cancers, particularly hematological cancers and solid tumors, in a subject having a deregulated lymphocyte receptor signaling pathway by administering to a subject a FABP5 inhibitor.
    Type: Application
    Filed: September 3, 2021
    Publication date: December 28, 2023
    Applicant: Aurigene Oncology Limited
    Inventors: Muralidhara Ramachandra, Leena Khare, Dinesh Chikkanna, Vijayashankar Nataraj, Sunil Kumar Panigrahi
  • Substituted Alkynylene Compounds As Anticancer Agents
    Publication number: 20230210847
    Abstract: The present invention relates to substituted alkynylene compounds represented by the compounds of formula (I), pharmaceutically acceptable salts and stereoisomers thereof. The present invention further provides the therapeutic uses of the compounds of formula (I) as anti-cancer agents.
    Type: Application
    Filed: March 10, 2023
    Publication date: July 6, 2023
    Inventors: Dinesh CHIKKANNA, Vinayak V. Khairnar, Muralidhara Ramachandra, Leena Khare Satyam
  • 1,2,4-Oxadiazole Derivatives as Immunomodulators
    Publication number: 20230167076
    Abstract: The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.
    Type: Application
    Filed: November 7, 2022
    Publication date: June 1, 2023
    Applicant: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways
    Publication number: 20230144653
    Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.
    Type: Application
    Filed: January 5, 2023
    Publication date: May 11, 2023
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Chennakrishnareddy Gundala
  • Substituted alkynylene compounds as anticancer agents
    Patent number: 11633394
    Abstract: The present invention relates to substituted alkynylene compounds represented by the compounds of formula (I), pharmaceutically acceptable salts and stereoisomers thereof. The present invention further provides the therapeutic uses of the compounds of formula (I) as anti-cancer agents.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: April 25, 2023
    Assignee: AURIGENE ONCOLOGY LIMITED
    Inventors: Dinesh Chikkanna, Vinayak V. Khairnar, Muralidhara Ramachandra, Leena Khare Satyam
  • 1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators
    Publication number: 20230110077
    Abstract: The present invention relates to 1,2,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.
    Type: Application
    Filed: October 10, 2022
    Publication date: April 13, 2023
    Applicant: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • CONJOINT THERAPIES FOR IMMUNOMODULATION
    Publication number: 20230081191
    Abstract: The present disclosure relates to methods comprising administering compounds that inhibit VISTA and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways with a compound that inhibits TIM-3 and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA, TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Application
    Filed: October 5, 2022
    Publication date: March 16, 2023
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Raghuveer K. Ramachandra, Adam S. Lazorchak, Timothy L. Wyant
  • DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS
    Publication number: 20230062570
    Abstract: The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Application
    Filed: October 7, 2022
    Publication date: March 2, 2023
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty S. Naremaddepalli, Nagaraj Gowda
  • 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways
    Patent number: 11560403
    Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: January 24, 2023
    Assignee: AURIGENE ONCOLOGY LIMITED
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Chennakrishnareddy Gundala
  • 1,2,4-oxadiazole derivatives as immunomodulators
    Patent number: 11512060
    Abstract: The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: November 29, 2022
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • Conjoint therapies for immunomodulation
    Patent number: 11497735
    Abstract: The present disclosure relates to methods comprising administering compounds that inhibit VISTA and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways with a compound that inhibits TIM-3 and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA, TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: November 15, 2022
    Assignees: Aurigene Discovery Technologies Limited, Curis, Inc.
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Raghuveer K. Ramachandra, Adam S. Lazorchak, Timothy L. Wyant
  • Dual inhibitors of TIM-3 and PD-1 pathways
    Patent number: 11497734
    Abstract: The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: November 15, 2022
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty S. Naremaddepalli, Nagaraj Gowda
  • 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
    Patent number: 11465976
    Abstract: The present invention relates to 1,2,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.
    Type: Grant
    Filed: August 1, 2020
    Date of Patent: October 11, 2022
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • COMBINATION OF SMALL MOLECULE CD-47 INHIBITORS WITH OTHER ANTI-CANCER AGENTS
    Publication number: 20220241248
    Abstract: The present invention relates to a composition of a CD47-SIRP? blocking agent and one or more anti-cancer agent(s), where the CD47-SIRP? blocking agents are represented by a compound of formula (I). The present invention also relates to a method of treating a cancer in a subject by administering a therapeutically effective amount of a CD47-SIRP? blocking agent represented by formula (I) in combination with one or more anti-cancer agent(s).
    Type: Application
    Filed: April 25, 2022
    Publication date: August 4, 2022
    Inventors: Muralidhara Ramachandra, Pottayil Govindan Nair Sasikumar, Girish Chandrappa Daginakatte, Kiran Aithal Balkudru
  • Combination of small molecule CD-47 inhibitors with other anti-cancer agents
    Patent number: 11311517
    Abstract: The present invention relates to a composition of a CD47-SIRP? blocking agent and one or more anti-cancer agent(s), where the CD47-SIRP? blocking agents are represented by a compound of formula (I). The present invention also relates to a method of treating a cancer in a subject by administering a therapeutically effective amount of a CD47-SIRP? blocking agent represented by formula (I) in combination with one or more anti-cancer agent(s).
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: April 26, 2022
    Assignee: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
    Inventors: Muralidhara Ramachandra, Pottayil Govindan Nair Sasikumar, Girish Chandrappa Daginakatte, Kiran Aithal Balkudru
  • 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling
    Patent number: 11274123
    Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 15, 2022
    Assignee: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Chennakrishnareddy Gundala
  • Substituted Alkynylene Compounds As Anticancer Agents
    Publication number: 20210379055
    Abstract: The present invention relates to substituted alkynylene compounds represented by the compounds of formula (I), pharmaceutically acceptable salts and stereoisomers thereof. The present invention further provides the therapeutic uses of the compounds of formula (I) as anti-cancer agents.
    Type: Application
    Filed: January 17, 2019
    Publication date: December 9, 2021
    Applicant: Aurigene Discovery Technologies Limited
    Inventors: Dinesh Chikkanna, Vinayak V. Khairnar, Muralidhara Ramachandra, Leena Khare Satyam